The World Health Organisation,(WHO) has confirmed that Cecolin®, a fourth prequalified human papillomavirus (HPV) vaccine, can be administered in a single-dose schedule.
This decision is based on new data that aligns with WHO’s 2022 recommendations, aimed at expanding access to cervical cancer prevention.
Unlike most other cancers, we have the ability to eliminate cervical cancer, along with its painful inequities,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “By adding another option for a one-dose HPV vaccination schedule, we have taken another step closer to consigning cervical cancer to history.”
Cervical cancer is responsible for over 660,000 cases globally each year, with more than 95% linked to HPV.
Tragically, a woman dies from this preventable disease every two minutes, primarily in low- and middle-income countries, particularly in Africa. “Nineteen of the 20 hardest-hit countries by cervical cancer are in Africa,” noted Dr. Ghebreyesus.
The introduction of HPV vaccines has faced challenges, particularly global supply shortages since 2018. Production issues earlier this year exacerbated these shortages, limiting access for millions of girls.
“Having 90% of girls fully vaccinated with the HPV vaccine by age 15 is our target for eliminating cervical cancer,” said Dr. Kate O’Brien, WHO’s Director of Immunisation, Vaccines, and Biologicals. “This addition of a single-dose option means countries will have more choices to reach their vaccination targets.”
According to a statement made public by the organisation, as of September 2024, 57 countries have implemented a single-dose schedule, with coverage among girls aged 9-14 increasing from 20% in 2022 to 27% in 2023, translating to an estimated 6 million additional girls vaccinated.
In a broader effort to combat cervical cancer, global partners have pledged nearly $600 million in new funding, including substantial contributions from the Bill & Melinda Gates Foundation and the World Bank.
